Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?
Authors Lieuw K
Received 16 February 2017
Accepted for publication 17 May 2017
Published 15 June 2017 Volume 2017:8 Pages 67—73
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Rajendra Narayan Mitra
Peer reviewer comments 2
Editor who approved publication: Dr Martin Bluth
1Department of Pediatrics, Walter Reed National Military Medical Center, 2Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
Abstract: Hemophilia A (HA) is a common bleeding disorder caused by the deficiency of factor VIII (FVIII) with an incidence of ~1 in 5000 male births. Replacement of FVIII is necessary to prevent and treat bleeding episodes. However, with multiple new drugs in addition to old standards, choosing among the different FVIII treatment options is harder than ever. There are FVIII products that are plasma derived or recombinant, FVIII products designed to extend the half-life of FVIII, and the first single-chain FVIII product, recombinant factor VIII single chain (rFVIII-SC). As development of inhibitors to FVIII continues to be a major problem in the care of HA patients, recent studies showing lower rates of inhibitor development with plasma-derived FVIIII products versus recombinant FVIII products have made choosing among the many options now available even more complex. Although still unproven, extended half-life (EHL) products may provide the hope of decreased immunogenicity but need further testing in previously untreated patients (PUPs). This review highlights some of the differences between FVIII products currently available and hopefully assists the clinician to decide which FVIII product to choose for their patients.
Keywords: hemophilia, hemophilia A, factor VIII, recombinant factor VIII single chain, extended half-life factor VIII, immunogenicity, bleeding disorder, inhibitor development
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]